Employees: 4,553
Size Evotec (EVT.DE) is a Germany Health Care company (Miscellaneous Commercial Services) with a market value of $532M, the 172nd largest of 198 Germany companies the cockpit tracks. Shares closed at €2.73 on 18 Nov 2026.
Performance Over six months the shares fell 45.5%, against +25.7% for the median peer and -0.9% for the Germany market (cap-weighted) — 2nd lowest of 9 in its peer set.
Growth Revenue fell 5.0% over the last twelve months (peer median +6.7%); the operating margin is -15.4% (peer median -58.4%).
Valuation It trades at 0.8× enterprise value to sales against a peer median of 10.0× (2nd cheapest of 7).
Capital Return on invested capital runs 18.0 points below its cost of capital (7.3% WACC).
Credit Evotec has 1 bond outstanding ($129M).
Next results Next results expected around 14 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €718M | €788M | €797M | €781M | €751M |
| Revenue growth | — | -1% | +2% | +4% | — |
| Gross profit | €95.1M | €65.2M | €65.9M | €175M | €174M |
| EBITDA | -€16.7M | -€41.4M | -€69.4M | -€7.16M | €13.0M |
| Net income | -€181M | -€104M | -€196M | -€83.9M | -€176M |
| Free cash flow | -€122M | -€82.0M | -€99.5M | -€179M | €21.8M |
| Capital expenditure | €45.3M | €82.6M | €132M | €216M | €181M |
| Total debt | €482M | €448M | €439M | €626M | €507M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EVT.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.2% | -2.5% | 4th highest of 9 |
| 6-month return | -45.5% | +25.7% | 2nd lowest of 9 |
| Distance from 52-week high | -59.5% | -29.4% | 2nd lowest of 9 |
| Revenue growth (TTM) | -5.0% | +6.7% | 2nd lowest of 6 |
| Operating margin | -15.4% | -58.4% | 4th highest of 7 |
| EV / Sales | 0.8× | 10.0× | 2nd cheapest of 7 |
| ROIC minus cost of capital | -18.0 pp | -8.9 pp | 2nd lowest of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Evotec EVT.DE | Germany | $532M | -46% | -5% | -15% | 0.8× | n/a | n/a |
| Adlai Nortye Ltd. Sponsored ADR ANL | United States | $610M | -23% | n/a | -134% | 22.3× | n/a | n/a |
| Oculis OCS | United States | $456M | -74% | n/a | n/a | n/a | n/a | n/a |
| Evolent Health EVH | United States | $445M | +2% | +14% | -1% | 0.5× | 14.0% | +15.2% |
| SBC Medical SBC | United States | $645M | +94% | +7% | 40% | 2.6× | -15.7% | +6.7% |
| Tectonic Therapeutic TECX | United States | $420M | -27% | n/a | n/a | n/a | n/a | n/a |
| OmniAb OABI | United States | $741M | +97% | +91% | -116% | 17.3× | 60.6% | -31.9% |
| Silence Therapeutics PLC Sponsored ADR SLN | United States | $1.23B | +244% | -98% | -11,920% | 2,161.6× | n/a | n/a |
| Fortrea FTRE | United States | $1.98B | +50% | -3% | 2% | 1.1× | 31.9% | +1.1% |
Evotec has 1 bond outstanding with $129M face value.